Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open-Label, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Conditions
Interventions
Efmarodocokin Alfa
Locations
8
United States
City of Hope
Duarte, California, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
University of Miami Miller School of Medicine; Clinical Reseach Building
Miami, Florida, United States
University of Chicago
Chicago, Illinois, United States
University of Kansas Med Ctr; Int med/Allgy/Immun/Rheum
Kansas City, Kansas, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
November 19, 2020
Primary Completion Date
February 24, 2023
Completion Date
February 24, 2023
Last Updated
April 11, 2024
NCT07070674
NCT06936566
NCT02611180
NCT06075706
NCT06394895
NCT06949267
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions